Top Page
PYC Therapeutics Limited
(Sydney:PYC)
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
PYC Therapeutics Limited Business Overview & Revenue Model
PYC Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.66M | 23.49M | 22.06M | 15.81M | 16.04M | 3.07M |
| Gross Profit | 11.35M | 23.49M | 22.06M | 14.92M | 15.20M | 2.45M |
| EBITDA | -59.80M | -52.88M | -54.55M | -38.25M | -29.39M | -21.04M |
| Net Income | -47.56M | -50.30M | -37.73M | -22.79M | -13.86M | -17.77M |
Balance Sheet | ||||||
| Total Assets | 159.13M | 183.28M | 91.24M | 37.17M | 45.35M | 57.94M |
| Cash, Cash Equivalents and Short-Term Investments | 120.69M | 153.05M | 66.87M | 15.57M | 29.11M | 51.50M |
| Total Debt | 1.26M | 1.02M | 1.11M | 315.49K | 943.77K | 730.35K |
| Total Liabilities | 11.80M | 13.27M | 10.18M | 8.72M | 5.15M | 4.02M |
| Stockholders Equity | 147.18M | 169.57M | 80.50M | 27.75M | 39.35M | 53.04M |
Cash Flow | ||||||
| Free Cash Flow | -66.22M | -52.54M | -38.90M | -24.91M | -22.17M | -12.38M |
| Operating Cash Flow | -65.75M | -51.56M | -38.59M | -24.42M | -21.78M | -11.79M |
| Investing Cash Flow | -463.80K | -975.40K | -307.04K | -477.12K | 32.68M | -15.52M |
| Financing Cash Flow | 138.63M | 138.66M | 90.19M | 11.44M | -182.36K | 38.56M |
PYC Therapeutics Limited Technical Analysis
PYC Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$508.53M | 14.96 | 13.29% | 0.38% | 7.76% | 1.55% | |
53 Neutral | AU$115.34M | -2.00 | -131.13% | ― | 456.50% | -457.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.43B | -10.86 | -40.23% | ― | ― | -5.70% | |
49 Neutral | AU$582.12M | -3.40 | -35.86% | ― | ― | -19.21% | |
47 Neutral | AU$1.41B | -5.54 | -54.37% | ― | ― | -29.93% | |
42 Neutral | AU$738.77M | -4.51 | 132.37% | ― | -80.08% | 59.91% |
PYC Therapeutics Limited Corporate Events
PYC Therapeutics has disclosed a change in director interests, with CEO Dr. Rohan Hockings increasing his direct holding by acquiring 80,010 ordinary shares through participation in a retail entitlement offer, bringing his total to 213,360 shares. In addition, subject to shareholder approval under the company’s long-term incentive plan, he is to be granted 1.5 million unlisted options exercisable at $2.52 over 48 months, further aligning executive incentives with the company’s equity performance.
The updated equity position and proposed option grant underscore the company’s use of capital management and incentive structures to retain and motivate key leadership. These changes may signal internal confidence in PYC Therapeutics’ prospects and are likely to be monitored by investors assessing governance, dilution potential, and the alignment of management interests with those of shareholders.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has applied for quotation of 10,573,060 new fully paid ordinary shares on the Australian Securities Exchange, with an issue date of March 9, 2026. The additional securities, issued under a previously announced transaction, will expand the company’s quoted share capital and may influence its market liquidity and ownership structure for existing and prospective investors.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has applied for quotation on the ASX of 31,197,631 new fully paid ordinary shares, with an issue date of March 6, 2026. The securities arise from previously announced transactions and their quotation will expand the company’s listed share base, potentially increasing liquidity and broadening its investor participation.
The move to quote these additional shares reflects ongoing capital-related activity that may support PYC Therapeutics’ funding capacity for its therapeutic development programs. The enlarged pool of tradable securities could influence market dynamics around the stock, including trading volumes and ownership structure among existing and new shareholders.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has appointed Daniel Coletta as joint company secretary, effective immediately, alongside long-serving secretary Kevin Hart, who will retire at the end of March 2026 after nearly nine years in the role. The Board highlighted that Coletta’s appointment ahead of Hart’s departure is designed to ensure a seamless transition of company secretarial responsibilities and maintain continuity in governance functions.
Coletta is an experienced Chartered Secretary who currently serves as company secretary to several ASX-listed and unlisted public companies, specialising in secretarial, governance, finance and corporate advisory services. Under ASX Listing Rule 12.6, he will assume responsibility for communications with the exchange on listing rule matters, reinforcing PYC’s compliance and corporate governance framework as it advances its RNA therapeutic programs.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has completed the retail component of its pro rata accelerated non-renounceable entitlement offer, raising about $47 million at $1.50 per new share. The offer saw applications for roughly 31 million shares, including additional applications of up to 100% of entitlements, representing a 40% take-up by eligible retail shareholders.
New shares from the retail offer are scheduled to be issued and begin trading on the ASX in early March, ranking equally with existing shares. Around 11 million of the approximately 46 million untaken retail shares will be issued to underwriters, while the remaining roughly 35 million may be placed with new or existing investors within three months at not less than the original offer price.
This retail raise follows an earlier institutional component and placement that secured about $537 million, significantly strengthening PYC’s capital position. The combined funding bolsters the company’s ability to advance its RNA therapeutic programs and may enhance its standing in the competitive genetic medicines sector.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has released a Q1 2026 investor update outlining the status of its business and drug development pipeline, emphasizing that its candidates are investigational and not yet approved by regulators. The company stresses that the information is for corporate communication only, not an offer or recommendation, and that forward-looking statements are subject to significant risks and uncertainties.
The update also notes that certain data are derived from public and industry sources that have not been independently verified, cautioning investors not to place undue reliance on such information. Overall, PYC positions this update as contextual information to be read alongside past and future announcements, underscoring that it should not be used as a standalone basis for investment decisions.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has lodged its Appendix 4D and interim financial statements for the half-year ended 31 December 2025 with the ASX. The release signals continued progression of the company’s clinical-stage RNA therapeutic programs and provides investors with updated financial disclosure as PYC advances its monogenic disease pipeline.
The board-approved filing underscores the company’s commitment to regulatory transparency as it develops its proprietary RNA drug delivery platform. Stakeholders will look to these interim accounts for insight into PYC’s funding position and operational runway amid a rapidly growing and commercially validated RNA therapeutics market.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has applied for quotation on the ASX of 354,782,201 new fully paid ordinary shares, with an issue date of 12 February 2026. The securities are being admitted to quotation following a previously announced transaction, expanding the company’s listed share base and potentially enhancing its market liquidity and access to capital for future development activities.
The move signals a further step in PYC’s capital markets strategy as it progresses its therapeutics pipeline and seeks broader investor participation. The enlarged register may have implications for existing shareholders through dilution but could also support the company’s long-term funding needs and visibility within the biotechnology sector.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has commenced the retail component of its previously announced 3-for-5 pro rata accelerated non-renounceable entitlement offer, confirming the dispatch of retail offer booklets and personalised entitlement and acceptance forms to eligible retail shareholders. The Retail Entitlement Offer opened on 9 February 2026 and is scheduled to close at 5.00pm AEDT on 27 February 2026, giving retail investors a defined window to participate in the company’s capital raising, which is expected to support its RNA therapy development pipeline and broader strategic objectives.
The company is directing eligible investors to review the Retail Offer Booklet carefully and to seek professional advice before making any investment decisions, underlining the complexity and risk profile of biotech equity offerings. The entitlement structure and accelerated timetable reflect PYC Therapeutics’ effort to efficiently secure funding while maintaining pro rata participation for existing shareholders, a move that could influence its capital structure and liquidity as it advances clinical programs in genetic disease.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics is launching a sizeable equity raising through a pro-rata accelerated non-renounceable entitlement offer, with eligible shareholders invited to subscribe for three new shares for every five held at A$1.50, to raise up to about A$525 million before costs. In parallel, it is conducting a placement to U.S. specialist life sciences investors targeting a further A$128 million, reinforcing its capital base for ongoing RNA therapy programs while confirming that certain retail shareholders are ineligible to participate in the retail component of the offer.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has opened the retail component of its previously announced 3-for-5 pro rata accelerated non-renounceable entitlement offer, giving eligible retail shareholders in Australia and New Zealand the opportunity to participate. The Retail Entitlement Offer opens on 9 February 2026 and is scheduled to close at 5:00 p.m. AEDT on 27 February 2026, with documentation and participation instructions being dispatched electronically or by letter to eligible investors.
The move underscores PYC’s ongoing capital-raising efforts to support its RNA therapeutic pipeline and could broaden its retail investor base while reinforcing shareholder participation in the company’s funding strategy. Eligible retail investors are urged to review the retail offer materials carefully and seek professional advice before deciding whether to take up their entitlements, highlighting the importance of informed decision-making amid continued development of PYC’s monogenic disease programs.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics will host an investor webinar on 24 February 2026, offering shareholders an update on its recent capital raise and providing a detailed overview of the progress and outlook for each of its four drug development programs. The session, accessible both in person in Perth and online, underscores the company’s effort to maintain transparency with investors as it deploys new capital to advance its clinical-stage RNA therapy pipeline targeting monogenic genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has closed the institutional placement and institutional component of its pro-rata accelerated non-renounceable entitlement offer, securing commitments of A$537 million at A$1.50 per new share from leading US specialist life sciences investors and Australian institutional investors. With an existing A$200 million underwriting agreement from major shareholders now activated following the capital raised so far, the company is assured of raising a minimum of A$600 million once the retail entitlement offer is completed, extending its cash runway through to calendar year 2030 and funding key clinical milestones, including human safety and efficacy data readouts for all four of its drug candidates, thereby strengthening its balance sheet and strategic positioning in the precision genetic medicine sector.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has announced a proposed capital raising through an accelerated non-renounceable entitlement offer and a separate placement of ordinary fully paid shares, together amounting to a potential issue of 435,445,335 new shares. The accelerated offer, which includes institutional and retail components, and the additional placement are structured to raise new equity capital, with defined ex-entitlement, record, closing, and issue dates, and are expected to strengthen the company’s balance sheet and provide funding flexibility for its ongoing operations and strategic initiatives, potentially affecting existing shareholders through dilution but improving the company’s financial capacity.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has launched a pro-rata non-renounceable entitlement offer, allowing eligible shareholders in Australia, New Zealand and certain other jurisdictions to subscribe for three new fully paid ordinary shares for every five shares held as at 4.00pm (Perth time) on 4 February 2026. The offer will be conducted without a disclosure document under Part 6D.2 of the Corporations Act, with the company confirming ongoing compliance with its financial reporting and continuous disclosure obligations, stating there is no excluded information to disclose and indicating that the new share issue is not expected to materially affect control of the company, thereby limiting potential dilutionary or governance impacts for existing shareholders.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has launched an equity raising initiative comprising an accelerated non-renounceable entitlement offer to eligible institutional and retail shareholders and a share placement to institutional investors, all involving new fully paid ordinary shares. The company positions the offer as informational in nature rather than formal investment advice, emphasising that it is not a prospectus and that participation decisions should be based on investors’ own circumstances and independent advice, while also stressing compliance with jurisdictional securities laws, including restrictions on distribution and offering in the United States.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has launched a major equity raising of up to A$653 million to advance four high-potential genetic disease drug candidates through key human efficacy milestones. The capital will be raised via a A$128 million placement to leading US specialist life sciences investors and a A$525 million accelerated non-renounceable entitlement offer to existing shareholders, both priced at A$1.50 per share, modestly discounted to the last traded price and theoretical ex-rights price. With binding commitments already secured for about A$560 million, the transaction is expected to fund the company into calendar year 2030 and support the progression of PYC-003 for polycystic kidney disease, PYC-002 for Phelan-McDermid syndrome, VP-001 for retinitis pigmentosa type 11 and PYC-001 for autosomal dominant optic atrophy into or towards registrational trials and clinical proof-of-concept read-outs, potentially transforming the company’s clinical profile and strengthening its position in the rare disease therapeutics sector.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has requested a trading halt in its securities on the ASX as it prepares a significant capital raising initiative. The halt will remain in place until either the completion announcement of the institutional component of a pro rata accelerated non-renounceable entitlement offer and an institutional placement, or the start of normal trading on 4 February 2026, whichever occurs first. The move signals an imminent equity raising that could strengthen the company’s balance sheet and fund its therapeutic development programs, with timing and structure designed to engage institutional investors while providing existing shareholders an opportunity to participate.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
In its fourth-quarter 2025 update, PYC Therapeutics reported continued progress across all four of its pipeline programs, highlighting key clinical milestones and positioning the company for important safety and efficacy read-outs over the next two years. The company established a favourable safety and tolerability profile for its polycystic kidney disease candidate in healthy volunteers, clearing the way for progression to patient studies; advanced its autosomal dominant optic atrophy program into a global repeat-dose trial aimed at demonstrating clinical proof of concept; presented longer-term data showing sustained vision improvement in patients with retinitis pigmentosa type 11 treated with its investigational therapy; and showcased preclinical data, including non-human primate results, to support moving its Phelan-McDermid syndrome candidate into clinical trials. Collectively, these developments underscore PYC’s execution against its clinical roadmap and strengthen its positioning as an emerging player in RNA therapeutics for high-unmet-need genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has proposed, subject to shareholder approval, the issuance of 1.5 million unlisted options to managing director Dr Rohan Hockings under its Long Term Incentive Plan, with a four-year expiry, growth-oriented exercise price of $2.52 and staged vesting over 12 and 24 months. The board says the move follows a broader review of retention incentives for key personnel driving the company’s RNA therapy pipeline and is designed to align Hockings’ remuneration with shareholder value creation and the rigorous governance and execution standards required as PYC advances its precision medicine programs.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has issued an updated notification to the ASX correcting a typographical error in a previously lodged Appendix 3G relating to unquoted equity securities. The company clarified that the option strike price for the relevant securities is A$2.52 per option rather than A$2.25 as originally recorded on 6 January 2026, a change that ensures accurate disclosure of the terms of its equity instruments for investors and other stakeholders but does not represent a new capital raising or change in overall financing strategy.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has released an updated corporate presentation timed with its participation at the 44th annual JP Morgan Healthcare Conference in San Francisco, underscoring its ongoing efforts to position itself among leading players in the RNA therapeutics field. By showcasing its precision RNA medicines pipeline and delivery platform at a major global healthcare investor forum, the company is seeking to raise its profile with investors and strategic partners, potentially supporting future funding, collaborations and advancement of its clinical programs for underserved genetic disease patients.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has proposed, subject to shareholder approval, the issuance of 1,000,000 unlisted options to director Professor Ian Constable under its Long Term Incentive Plan, matching the vesting conditions and A$1.80 strike price of options previously granted to its chairman upon appointment. The move, detailed alongside a Change of Director Interest Notice, underscores the company’s continued use of equity-based incentives to align board members with long-term shareholder value as it advances its RNA therapy pipeline for genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has issued 2.5 million unlisted employee options under its employee incentive scheme, effective 5 January 2026. The unquoted options are not intended to be listed on the ASX and form part of the company’s broader strategy to retain and incentivise key personnel, signalling continued reliance on equity-based compensation to support its development pipeline and align employees with future growth objectives.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has granted 2.5 million unlisted options to senior employees under its Long Term Incentive Plan, aiming to better align staff incentives with shareholder interests ahead of a series of key human clinical data read-outs expected in 2026. The move underscores the company’s focus on retaining and motivating key talent as it approaches potentially value-defining milestones in its precision RNA medicine programs, signalling an effort to strengthen internal commitment during a pivotal year for its clinical and commercial trajectory.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has disclosed a change in director Peter Coleman’s interests, reporting the issue of 2,000,000 unlisted options as part of his remuneration. The options, granted pursuant to his letter of appointment, carry an exercise price of $1.80 and expire on 19 November 2028, marking Coleman’s first holding of these securities and signalling the company’s use of equity-based incentives to align director compensation with shareholder value.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has notified the market that it will issue 2,000,000 unlisted options as unquoted equity securities, effective 23 December 2025. The creation of this new class of unlisted options indicates the company is using equity-based instruments, likely for capital management or incentive purposes, which may affect ownership structure and align stakeholders’ interests with the company’s longer-term performance.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has issued 2,000,000 unlisted options to director Peter Coleman under an exception to ASX Listing Rule 10.12, with associated terms and conditions and regulatory notices to be filed. The move underscores the company’s use of equity-based incentives in its governance and remuneration framework as it advances its clinical-stage RNA therapeutic programs for genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics announced positive safety outcomes from Part A of its Phase 1a/1b single-ascending-dose clinical trial of PYC-003, reporting that single doses up to 4 mg/kg in healthy volunteers were safe and well tolerated with no treatment-emergent serious adverse events. Based on these data, the company has begun dosing PKD patients in Part B of the study at 1.2 mg/kg and is preparing to initiate a repeat-dose Part C in the first half of 2026, positioning PYC-003 to progress into a planned single registrational Phase 2/3 trial aimed at supporting a future new drug application and advancing its strategy in the PKD treatment landscape.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.